Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. is positioned favorably due to its innovative fibroblast-based therapies aimed at addressing significant unmet medical needs in chronic diseases, with promising preliminary outcomes in wound healing and psoriasis treatment that may enhance its therapeutic portfolio. The company's extensive intellectual property estate and focus on scalable manufacturing could lead to reduced production costs and regulatory hurdles, bolstering its competitive advantage in the cell therapy market. As the company advances its manufacturing preparations for ongoing clinical trials and IND-enabling studies, there is potential for substantial progress in development timelines, which may positively impact investor sentiment and the overall valuation of its stock.

Bears say

FibroBiologics faces significant risks that could adversely impact its financial outlook, including the potential failure of its developmental candidates to achieve peak revenue estimates due to market size limitations and patient penetration rates. The company reported a net loss of $5.8 million for the third quarter of 2025, reflecting substantial financial difficulties alongside an over 80% decline in its stock price year-to-date, contrasting with an overall industry increase of 20%. Further compounding these challenges, the firm may struggle to secure the necessary capital to fund operations and continue program development, which could hinder its long-term viability.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.